Methadone & Other Opiate Maintenance

[Courtesy of North American Opiate Medication Initiative (NAOMI)] For Immediate Release: October 17, 2008 Contact: Julie Schneiderman at (604) 806-8380 Results show that North America’s first heroin therapy study keeps patients in treatment, improves their health and reduces illegal activity VANCOUVER, BC, October 17, 2008 – Researchers from the North American Opiate Medication Initiative (NAOMI Study) today released final data on the primary outcomes from the three-year randomized controlled clinical trial. “Our data show remarkable retention rates and significant improvements in illicit heroin use, illegal activity and health for participants receiving injection assisted therapy, as well as those assigned to optimized methadone maintenance,” says Dr. Martin Schechter, NAOMI’s Principal Investigator, Centre for Health Evaluation and Outcome Sciences and Professor and Director, University of British Columbia School of Population and Public Health. “Prior to NAOMI, all of the study participants had not benefited from repeated standard addiction treatments. Society had basically written them off as impossible to treat.” The data, which was collected from 251 participants at sites in Vancouver and Montreal, demonstrate that a combination of optimized methadone maintenance therapy (MMT) and heroin assisted treatment (HAT) can attract and retain the most difficult-to-reach and the hardest-to-treat individuals who have not been well served by the existing treatment system. Key findings at the 12-month point of the treatment-phase of the study showed that HAT and MMT achieved high retention rates: 88 per cent and 54 per cent respectively. Illicit heroin use fell by almost 70 per cent. The proportion of participants involved in illegal activity fell by almost half from just over 70 per cent to approximately 36 per cent. Similarly, the number of days of illegal activity and the amount spent on drugs both decreased by almost half. In fact, participants once spending on average $1,500 per month on drugs reported spending between $300-$500 per month by the end of the treatment phase. Marked improvements were also seen in participants’ medical status with scores improving by 27 per cent. Of particular note amongst the findings, participants receiving hydromorphone (DilaudidTM) instead of heroin on a double-blind basis (neither they nor the researchers knew) did not distinguish this drug from heroin. Moreover, hydromorphone – an opiate licensed for the relief of pain - appeared to be equally effective as heroin, although the study was not designed to test this conclusively. According to the NAOMI Study Investigators, further research could help to confirm these observations, allowing hydromorphone assisted therapy to be made more widely available. While a comprehensive health economics study is pending, researchers have already determined that the cost of continued treatment is much less than that of relapse. “We now have evidence to show that heroin-assisted therapy is a safe and effective treatment for people with chronic heroin addiction who have not benefited from previous treatments. A combination of optimal therapies – as delivered in the NAOMI clinics - can attract those most severely addicted to heroin, keep them in treatment and more importantly, help to improve their social and medical conditions,” explains Schechter. A summary report of the findings and background information on the study are available at: www.naomistudy.ca.

FOR IMMEDIATE RELEASE: February 23, 2008 Contact Persons: Carol Sholiton, Founder/Director, E: [email protected]; Chuck Hilger, Colonial Management Group, E: [email protected] Colonial Management Group (CMG) Now offering Suboxone in all Clinics Colonial Management Group (CMG), with 54 opiate addiction treatment centers located throughout the United States, announced that as of January 1, 2008 all of their facilities are now offering Buprenorphine (Brand name Suboxone) in addition to their Methadone Maintenance Program. Suboxone (Buprenorphine/Naloxone) received approval by the FDA on October 8, 2002. It is state of the art medication to treat the medical condition of Opioid addiction. It is improving the quality of life for patients in recovery and giving them hope, dignity, and the ability to have a normal life again. CMG focuses the work in their clinics on managing the disease of addiction and strive to improve their patients' quality of life. This involves implementing the most current research findings in the treatment of their patients.